Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2311-2316

  Fendler, Wojciech ^a   Pietrzak, Iwona ^a   Brereton, Melissa F ^b   Lahmann, Carolina ^b   Gadzicki, Mariusz ^a   Bienkiewicz, Malgorzata ^a   Drozdz, Izabela ^a   Borowiec, Maciej ^a   Malecki, Maciej T ^c   Ashcroft, Frances M ^b   Mlynarski, Wojciech M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; SULFONYLUREA; INWARDLY RECTIFYING POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BRAIN REGION; CEREBELLUM; CEREBELLUM DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEND SYNDROME; DIABETES MELLITUS; DISEASE SEVERITY; EPILEPSY; FEMALE; GENE; GENE MUTATION; GENETIC CODE; HUMAN; IDEND SYNDROME; KCNJ11 GENE; MALE; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; RIGHT HEMISPHERE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; INFANT; METABOLISM; NEWBORN; PRESCHOOL CHILD; VASCULARIZATION;

ADOLESCENT; CEREBELLUM; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; FEMALE; GLYBURIDE; HUMANS; INFANT; INFANT, NEWBORN; MALE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SULFONYLUREA COMPOUNDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84885981289     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2166     Document Type: Article

References (18)

1. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl JMed 2004;350:1838-1849
2. Gloyn AL, Diatloff-Zito C, Edghill EL, et al. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur J Hum Genet 2006;14:824-830
3. Mlynarski W, Tarasov AI, Gach A, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.Nat Clin Pract Neurol 2007;3:640-645
4. Malecki MT, Skupien J, Klupa T, et al. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity. Diabetes Care 2007;30:147-149
5. Kapucu OL, Nobili F, Varrone A, et al. EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging 2009;36:2093-2102
6. Barthel H, Wiener M, Dannenberg C, Bettin S, Sattler B, KnappWH. Age-specific cerebral perfusion in 4- to 15-year-old children: a high-resolution brain SPET study using 99mTc-ECD. Eur JNuclMed 1997;24: 1245-1252
7. Tammaro P, Proks P, Ashcroft FM. Functional effects of naturally occurring KCNJ11 mutations causing neonatal diabetes on cloned cardiac KATP channels. J Physiol 2006;571:3-14
8. Tammaro P, Flanagan SE, Zadek B, et al. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications. Diabetologia 2008;51:802-810
9. Allen Brain Atlas Resources [Internet]. Seattle (WA): Allen Institute for Brain Science. 2009. Available from http://www.brain-map.org. Accessed 21 July 2012
10. Clark RH, McTaggart JS, Webster R, et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science 2010;329: 458-461
11. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53Dmutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2008;93:1054-1061
12. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, earlyonset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006;49:2559-2563
13. Battaglia D, Lin YW, Brogna C, et al. Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation. Pediatr Diabetes 2012;13:656-660
14. Slingerland AS, Hurkx W, Noordam K, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008;25: 277-281
15. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477
16. Girard CA, Shimomura K, Proks P, et al. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. Pflugers Arch 2006;453:323-332
17. Shimomura K, Girard CA, Proks P, et al. Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects. Diabetes 2006;55:1705-1712
18. Proks P, Girard C, Ashcroft FM. Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP. Hum Mol Genet 2005;14:2717-2726